XLR-12

XLR-12 is an experimental synthetic cannabinoid in the tetramethylcyclopropylindole family. It is structurally related to UR-144 and XLR-11, but has a 4,4,4-trifluorobutyl group attached to the indole nitrogen. Unlike many recreational synthetic cannabinoids, XLR-12 was developed as a research ligand and is notable for strong selectivity toward the CB₂ receptor.

Chemistry and identification

XLR-12 is (2,2,3,3-tetramethylcyclopropyl)[1-(4,4,4-trifluorobutyl)-1H-indol-3-yl]methanone. It retains the tetramethylcyclopropyl ketone group found in UR-144 and XLR-11, but replaces their pentyl-based side chains with a shorter trifluorinated butyl chain. UNODC lists XLR-12 as a synthetic cannabinoid receptor agonist (UNODC substance record: XLR-12).

Pharmacology

Published receptor-binding data describe XLR-12 as strongly CB₂-selective. A review of synthetic cannabinoid pharmacology reports a CB₂ Ki of approximately 0.09 nM and a CB₁ Ki of approximately 15 nM, indicating a marked preference for CB₂. The compound nevertheless retains measurable CB₁ affinity, so it is not completely inactive at the central receptor (The Chemistry and Pharmacology of Synthetic Cannabinoids, 2018).

The structure–activity research on this series examined how changes to the indole N-substituent influence CB₂ selectivity. The 4,4,4-trifluorobutyl chain in XLR-12 is associated with a substantially different receptor profile from the pentyl and 5-fluoropentyl chains in UR-144 and XLR-11 (Frost and colleagues, 2010).

Effects in experimental models

XLR-12 has primarily been studied as a cannabinoid receptor research ligand. Its CB₂ preference makes it relevant to investigations of peripheral cannabinoid signalling, including immune and inflammatory pathways. These laboratory findings do not establish a therapeutic effect in humans.

Neither a substantial body of human accounts nor a controlled clinical study establishes characteristic subjective effects. The psychoactive effects of recreational synthetic cannabinoids with strong CB₁ activity cannot simply be attributed to it.

Toxicity and research limitations

No well-characterised human case series, pharmacokinetic study or clinical safety assessment specific to XLR-12 was identified in the available sources. Its acute toxic range, metabolism, dependence potential and long-term effects remain uncertain.

XLR-12 is best understood as an experimental CB₂-preferring ligand. Its inclusion in synthetic cannabinoid databases does not establish widespread recreational use or a human intoxication profile.

Related compounds

XLR-12 is related to UR-144 and XLR-11. All three share the tetramethylcyclopropyl ketone indole framework, but their N-substituents produce different receptor profiles.